WednesdayNov 02, 2022 10:33 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Eliminates Some $13M in Debt

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has eliminated $13 million in company debt, resulting in a reduction of overall indebtedness from more than $30 million last year to less than $10 million currently. The company has been working to strengthen its financial balance sheet; it also recently eliminated some $13 million of company debt associated with Esousa Holdings LLC. According to the announcement, MULN believes this debt conversion will save more than $3.5 million in interest expenses. With less than $10 million left of outstanding indebtedness, Mullen is maintaining its strong financial health. “It’s been a…

Continue Reading

TuesdayNov 01, 2022 1:35 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

Continue Reading

TuesdayNov 01, 2022 1:23 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

Continue Reading

TuesdayNov 01, 2022 12:57 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading

MondayOct 31, 2022 1:52 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading

MondayOct 31, 2022 1:38 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures LOI for up to $100M to Help Fund next Stage of Growth

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has rapidly emerged as a leader amongst its peers – deploying its unique capabilities across a host of different environments, ranging from traffic systems in Cape Town, South Africa, to airport terminal monitoring in the U.S. “Cepton’s long-term automotive Tier 1 partner, Koito Manufacturing Co. Ltd., recently revealed that it had provided Cepton with a letter of intent representing an investment of up to $100 million to help fund Cepton’s next stage of growth as it seeks to scale its lidar solutions for mass deployment,” a recent…

Continue Reading

MondayOct 31, 2022 10:17 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Shares Responses from Participants of Its Strikingly Different FIVE EV Crossover Tour

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is seeing an overwhelmingly positive response to its Strikingly Different FIVE EV Crossover tour. Tour participants, including potential buyers and Mullen investors, who reserve a spot on the tour are enjoying the opportunity to ride the Mullen EV Crossover and personally interact with Mullen’s updated infotainment system, which features PERSONA, Mullen’s proprietary Personal Vehicle Assistant technology. PERSONA uses the latest facial recognition technology, which enables the vehicle to provide a highly personalized experience to every driver of the Mullen FIVE. The tour kicked off in Pasadena, California, last week, and has…

Continue Reading

FridayOct 28, 2022 12:39 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports Higher-than-Expected Preorders for Mullen FIVE Electric-SUV Crossover

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is accepting preorders for its Mullen FIVE vehicle, and the company’s Strikingly Different EV Crossover Tour has had a significant impact on those orders. The tour kicked off earlier this week, and preorders for the new SUV crossover quadrupled in the period leading up to and during the tour’s first stop in Pasadena, California. Those who attend the tour can take a test drive in the new EV, with a professional driver at the wheel; they also have an opportunity to interact with the vehicle’s innovative infotainment system and see…

Continue Reading

ThursdayOct 27, 2022 1:22 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol ("CBD") therapy. The study is evaluating Lexaria's patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well…

Continue Reading

ThursdayOct 27, 2022 12:07 pm

TinyGemsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Enters $100M Agreement with Koito Manufacturing

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has signed a binding investment agreement with its long-term automotive tier 1 partner and current shareholder, Koito Manufacturing Co. Ltd. The company anticipates using the funds — $100 million — for its next stage of growth as it grows its lidar solutions and looks toward mass deployment. The agreement has been approved by Cepton’s board of directors and calls for Koito to purchase $100 million of convertible preferred stock. According to the announcement, the shares will be convertible, beginning on the first anniversary of the issue date, into…

Continue Reading

Contact us: (512) 354-7000